Evidence map›Paper›PMID 39266569›Full record

ArticleNature communications2024

Nuclear lamin A/C phosphorylation by loss of androgen receptor leads to cancer-associated fibroblast activation.

Soumitra Ghosh, Jovan Isma, Paola Ostano, Luigi Mazzeo, Annagiada Toniolo, Monalisa Das, Joni R White, Christian Simon, G Paolo Dotto

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Soumitra GhoshPersonalised Cancer Prevention Unit, ORL Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. soumitra.ghosh@pilani.bits-pilani.ac.in.ORCID 0000-0002-8376-8677
Jovan IsmaDepartment of Immunobiology, University of Lausanne, Epalinges, Switzerland.
Paola OstanoCancer Genomics Laboratory, Edo and Elvo Tempia Valenta Foundation, Biella, Italy.
Luigi MazzeoDepartment of Immunobiology, University of Lausanne, Epalinges, Switzerland.
Annagiada TonioloDepartment of Immunobiology, University of Lausanne, Epalinges, Switzerland.ORCID 0000-0001-6332-6225
Monalisa DasDepartment of Immunobiology, University of Lausanne, Epalinges, Switzerland.ORCID 0000-0002-0939-5032
Joni R WhiteCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.ORCID 0000-0002-5428-960X
Christian SimonPersonalised Cancer Prevention Unit, ORL Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
G Paolo DottoPersonalised Cancer Prevention Unit, ORL Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. gdotto@mgh.harvard.edu.ORCID 0000-0002-1197-8448

Funding

GROWTH DIFFERENTIATION CONTROL IN PRIMARY KERATINOCYTES.R01AR039190 · NIAMS · YALE UNIVERSITY · PI DOTTO, GIAN-PAOLO · 1988 to 2021
$9.5M
Epigenetic control of skin homeostasis by the ULK3 nuclear kinaseR01AR078374 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI DOTTO, GIAN-PAOLO · 2021 to 2025
$2.4M
Androgen receptor function in melanomaR01CA269356 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DOTTO, GIAN-PAOLO · 2022 to 2025
$2.3M
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 859860Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01AR039190Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01AR078374Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01CA269356NCI NIH HHS R01 CA269356NIAMS NIH HHS R01 AR039190NIAMS NIH HHS R01 AR078374Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030B_176404
6 · The paper itself

Abstract

Alterations in nuclear structure and function are hallmarks of cancer cells. Little is known about these changes in Cancer-Associated Fibroblasts (CAFs), crucial components of the tumor microenvironment. Loss of the androgen receptor (AR) in human dermal fibroblasts (HDFs), which triggers early steps of CAF activation, leads to nuclear membrane changes and micronuclei formation, independent of cellular senescence. Similar changes occur in established CAFs and are reversed by restoring AR activity. AR associates with nuclear lamin A/C, and its loss causes lamin A/C nucleoplasmic redistribution. AR serves as a bridge between lamin A/C and the protein phosphatase PPP1. Loss of AR decreases lamin-PPP1 association and increases lamin A/C phosphorylation at Ser 301, a characteristic of CAFs. Phosphorylated lamin A/C at Ser 301 binds to the regulatory region of CAF effector genes of the myofibroblast subtype. Expression of a lamin A/C Ser301 phosphomimetic mutant alone can transform normal fibroblasts into tumor-promoting CAFs.

Indexed as

Cancer-Associated FibroblastsCell NucleusLamin Type AReceptors, AndrogenFibroblastsHumansMaleNuclear EnvelopePhosphorylationProtein Phosphatase 1Tumor MicroenvironmentAR protein, humanLamin Type ALMNA protein, humanProtein Phosphatase 1Receptors, Androgen

Identifiers

PMID39266569
PMCPMC11392952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.